From the Guidelines
Endocardial Pacemaker (Endopac) refers to a type of pacemaker that is implanted inside the heart to regulate heart rhythm. The term "Endopac" is not explicitly defined in the provided evidence, but based on the context, it appears to be related to pacemaker therapy.
- The primary function of a pacemaker is to treat bradyarrhythmias and tachyarrhythmias, and in some cases, it is combined with implantable defibrillators 1.
- Pacemaker therapy is primarily used to treat sinus node dysfunction, acquired atrioventricular block, and certain fascicular blocks, as well as to prevent and treat certain tachyarrhythmias and forms of neurocardiogenic syncope 1.
- The decision to implant a pacemaker depends on the presence of symptoms, and symptomatic bradycardia is the most common indication 1.
- Pacemaker therapy has been shown to reduce symptoms, improve quality of life, and in certain patient populations, improve survival 1.
- The technology behind pacemakers has evolved significantly over the years, from simple single-chamber, fixed-rate pacemakers to multichamber, rate-responsive units capable of pacing, cardioversion, and defibrillation 1.
- It is essential to note that the provided evidence does not explicitly define "Endopac," but based on the context, it appears to be related to pacemaker therapy, and the information provided is based on the general concept of pacemakers and their uses 1.
From the Research
Definition of Endocardial Pacemaker (Endopac)
There are no research papers to assist in answering this question as the provided studies do not mention Endocardial Pacemaker (Endopac).
Related Information
The provided studies discuss the Enriching New-Onset Diabetes for Pancreatic Cancer (END-PAC) model, which is used to identify patients at high risk of pancreatic cancer. Key points about the END-PAC model include:
- The model was developed and validated to determine the risk of pancreatic cancer in patients with new-onset diabetes 2, 3.
- The model uses factors such as change in weight, change in blood glucose, and age at onset of diabetes to assign a risk score 3.
- The model has been validated in various studies, with area under the curve (AUC) values ranging from 0.69 to 0.87 2, 3, 4, 5.
- The model has been shown to be effective in identifying patients at high risk of pancreatic cancer, with sensitivity and specificity values ranging from 54.2% to 80% and 75% to 85%, respectively 3, 4, 5.